do not combine dpp-4 inhibitors with glp-1 receptor agonists recommendation GLP-1-RA and in the management of type 2 diabetes Lesson: A Clinical Overview of

The systemically acting intranasally administered biologics (proteins and peptides) under clinical investigation as enrolled at clinicaltrials.gov was listed by Rohrer et al

Fibromyalgia, depression, or weight loss Weight loss Decrease in existing body weight

Half-life characteristics support typical research administration patterns

Muscle Building & Performance Increases lean mass and strength in resistance-trained adults Enhances muscle protein synthesis rates Improves exercise recovery and adaptation Reduces muscle damage markers post-exercise Tissue Repair & Recovery Accelerates healing of tendons and ligaments Enhances collagen synthesis and deposition Reduces recovery time from musculoskeletal injuries Supports surgical wound healing Metabolic Health Improves glucose disposal in insulin resistance Enhances insulin sensitivity by 34% in prediabetes Supports nutrient partitioning and utilization May reduce cardiovascular risk factors Additional Clinical Applications Important Consideration: All applications of IGF-1 LR3 are considered off-label use

- , , , , ,